Handelsavisen
prelaunch
Companies Healthcare SAI.MC
SA
SAI.MC BME Madrid Advanced Medical Equipment & Technology

Substrate Artificial Inteligence SA

€0,03
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Substrate Artificial Intelligence SA develops and commercializes advanced medical equipment and technology solutions, primarily serving the healthcare services and equipment sector.

Business. Substrate Artificial Inteligence SA (SAI.MC) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on the development and sale of medical devices. The company is headquartered in Spain and is primarily listed on the BME (Madrid) exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SAI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SAI.MC. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Substrate Artificial Inteligence SA (SAI.MC) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on the development and sale of medical devices. The company is headquartered in Spain and is primarily listed on the BME (Madrid) exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Substrate Artificial Intelligence SA has a basic and diluted share count of 111,437,057 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    Profitability metrics are not available for direct comparison to industry_config preferred metrics or cohort medians, as the company reported a loss per share of -0.28 EUR in the latest period, with a mean EPS estimate of -0.01 EUR for the upcoming period. This suggests the company is not yet generating positive returns on invested capital or operating margins, which are key metrics for the Advanced Medical Equipment & Technology industry.

    The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with overreliance on specific markets or customer segments. This lack of transparency could obscure potential vulnerabilities in the business model.

    Growth trajectory is uncertain, as no numeric deltas or revenue history are provided in the input data. Analysts have issued one "buy" recommendation and no "strong buy" or "sell" ratings, indicating a cautious but not enthusiastic outlook. The absence of historical revenue data limits the ability to project future performance.

    Risk factors include the inability to assess liquidity risk and the lack of disclosed capital structure details. The company has a low dilution potential based on current share counts, but no information is available on potential future dilution from equity offerings or convertible instruments.

    Recent events, such as filings or transcripts, are not included in the input data, so no specific developments can be cited to inform the company's current strategic direction or operational performance.

    Key takeaways
    • The company is classified in the Advanced Medical Equipment & Technology industry with high confidence.
    • No liquidity risk assessment is available due to missing balance-sheet data.
    • The company is currently reporting a loss per share, with no positive returns on invested capital or operating margins.
    • Analysts have issued one "buy" recommendation, with no "strong buy" or "sell" ratings.
    • Revenue concentration and geographic exposure are not disclosed, limiting visibility into market risks.
    • No recent events or filings are available to inform strategic or operational developments.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-04-30
    FY 2024 · Full-year highlights

    Revenue €17.5M, +103,5% YoY; Operating income +223,1% YoY.

    Revenue€17.5M+103,5 % YoY
    Operating income€9.3M+223,1 % YoY
    Net income€7.4M+183,4 % YoY
    Free cash flow€2.8M+134,1 % YoY
    EPS
    Operating cash flow€6.4M+272,2 % YoY
    Financials
    Income statement
    Revenue€17.5M
    Gross profit€13.5M
    Operating income€9.3M
    Net income€7.4M
    Margins
    Gross margin76.9%
    Operating margin53.0%
    Net margin42.1%
    FCF margin15.8%
    Balance sheet
    Total assets€61.3M
    Total liabilities€20.2M
    Total equity€41.1M
    Cash & equivalents
    Long-term debt€4.7M
    Cash flow
    Operating cash flow€6.4M
    CapEx-€6.3M
    Free cash flow€2.8M
    SBC
    P&L flow · revenue → net income
    Revenue €17.5MOperating costs €8.2MTax €1.9MNet income €7.4M
    Highlights
    • Revenue €17.5M, +103,5% YoY
    • Operating income +223,1% YoY
    • Net income +183,4% YoY
    • Free cash flow +134,1% YoY
    • Net margin 42.1%

    Valuation FY

    Market price
    €0,03
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,01
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-09 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,01
    Revenueno estimateno estimate19,4M EUR
    Operating incomeno estimateno estimate-3,0M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    Operating income · consensus-3,0M EUR
    EPS surprise
    −2 700,0 %
    reported vs consensus · miss
    Revenue surprise
    −55,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Substrate Artificial Inteligence SA Market data — financials · 2026-05-29
    • Substrate Artificial Inteligence SA Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Leadership

    • Lorenzo Serratosa GallardoExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SAI.MCCanonical
    BME Madrid · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2024-04-30 16:14 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 17.5M · Net EUR 7.4M
    2023-04-13 17:31 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 8.6M · Net EUR -8.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage